Literature DB >> 6465028

Electrophysiologic effects of propafenone on canine ischemic cardiac cells.

R H Zeiler, W B Gough, N El-Sherif.   

Abstract

The electrophysiologic effects of propafenone were studied by conventional microelectrode techniques in ischemic myocardial and Purkinje fibers from 1-day-old myocardial infarction in the dog. Propafenone reduced the amplitude and rate of rise of normal myocardial and Purkinje action potentials and had little effect on the resting potential. In the control state, both ischemic myocardial and Purkinje fibers had reduced resting potential, action potential amplitude and upstroke velocity. These fibers were more susceptible to the depressant effects of propafenone than normal fibers. Ischemic myocardial fibers were particularly sensitive to the actions of propafenone that resulted in marked depression of action potential characteristics, with little effect on resting potential. These changes resulted in cycle length-dependent conduction disorders in ischemic epicardial preparations. However, in ischemic endocardial preparations in which triggered activity could be initiated, propafenone reversibly suppressed the triggered activity. Termination of the triggered activity was preceded by slowing of the rate, which was attributed to a decrease in the rate of rise of the delayed afterdepolarizations. This activity terminated when the delayed afterdepolarization failed to attain threshold potential. This study suggests that propafenone has a membrane-anesthetic effect, with the abnormal fast channel in ischemic cells being more sensitive; propafenone depresses delayed afterdepolarizations in ischemic Purkinje fibers; and the actions of propafenone could result in an antiarrhythmic effect in vivo on both reentrant ventricular rhythms in ischemic myocardium and triggered rhythms in ischemic Purkinje fibers.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6465028     DOI: 10.1016/0002-9149(84)90210-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hyun Seok Hwang; Can Hasdemir; Derek Laver; Divya Mehra; Kutsal Turhan; Michela Faggioni; Huiyong Yin; Björn C Knollmann
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-01-26

Review 2.  Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

Review 3.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 4.  New antiarrhythmic drugs in pediatric use: propafenone.

Authors:  T Paul; J Janousek
Journal:  Pediatr Cardiol       Date:  1994 Jul-Aug       Impact factor: 1.655

5.  Effects of propafenone on function and metabolism in the ischemic working rat heart.

Authors:  T Nakamura; S Kashimoto; T Oguchi; T Kumazawa
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

Review 6.  The role of late I Na in development of cardiac arrhythmias.

Authors:  Charles Antzelevitch; Vladislav Nesterenko; John C Shryock; Sridharan Rajamani; Yejia Song; Luiz Belardinelli
Journal:  Handb Exp Pharmacol       Date:  2014

Review 7.  Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.

Authors:  A Capucci; G Boriani
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.